AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hoban, D. J.
Right arrow Articles by Zhanel, G. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoban, D. J.
Right arrow Articles by Zhanel, G. G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2001, p. 2147-2150, Vol. 45, No. 7
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.7.2147-2150.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Macrolide-Resistant Streptococcus pneumoniae in Canada during 1998-1999: Prevalence of mef(A) and erm(B) and Susceptibilities to Ketolides

Daryl J. Hoban,1,2 Aleksandra K. Wierzbowski,1 Kim Nichol,1 and George G. Zhanel1,2,3,4,*

Department of Medical Microbiology, Faculty of Medicine1 and Faculty of Pharmacy,3 University of Manitoba, and Departments of Medicine4 and Clinical Microbiology,2 Health Sciences Centre, Winnipeg, Manitoba, Canada

Received 22 January 2001/Returned for modification 2 March 2001/Accepted 9 April 2001

In this study (1998-1999), we collected 215 macrolide-resistant Streptococcus pneumoniae isolates from an ongoing Canadian Respiratory Organism Surveillance Study involving 23 centers representing all regions of Canada. The prevalence of erythromycin-resistant S. pneumoniae was 8% (215 of 2,688). Of the 215 isolates, 48.8% (105 of 215) were PCR positive for mef(A) and 46.5% (100 of 215) were PCR positive for erm(B). The ketolides telithromycin and ABT-773 demonstrated excellent activity against both mef(A) (MIC for 90% of strains [MIC90], 0.06 and 0.03 µg/ml, respectively) and erm(B) (MIC90, 0.06 and 0.03 µg/ml, respectively) strains of S. pneumoniae.


* Corresponding author. Mailing address: Department of Clinical Microbiology, Health Sciences Centre, MS673-820 Sherbrook Street, Winnipeg, Manitoba R3A 1R9, Canada. Phone: (204) 787-4902. Fax: (204) 787-4699. E-mail: ggzhanel{at}pcs.mb.ca.


Antimicrobial Agents and Chemotherapy, July 2001, p. 2147-2150, Vol. 45, No. 7
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.7.2147-2150.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2001 by the American Society for Microbiology. All rights reserved.